Table 4. Median survival time by E-RBC group and primary site.
|
Control
|
Efaproxiral
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Low E-RBC
|
High E-RBC
|
|||||||||
|
Log-rank
|
Cox
|
|||||||||
| Site | D/Na | MST (months) | D/Na | MST (months) | D/Na | MST (months) | HRb | P c | HRb | P c |
| All Patients | 198/242 | 4.47 | 103/118 | 4.93 | 69/98 | 7.10 | 0.63 | 0.0012 | 0.59 | <0.001 |
| NSCLC | 111/141 | 4.37 | 58/65 | 4.73 | 39/52 | 6.97 | 0.73 | 0.0937 | 0.69 | 0.056 |
| Breast | 41/48 | 4.47 | 16/22 | 7.33 | 10/24 | 25.72 | 0.25 | 0.0002 | 0.55 | 0.006 |
a
D=number of events (deaths); N=number of patients.
b
Hazard ratio.
c
Significance test between efaproxiral, High E-RBC group, and control arm.
E-RBC=efaproxiral red blood cell concentration; MST=median survival time; NSCLC=non-small-cell lung cancer.